Search

Displaying results 4331 - 4340 of 10000 in total
  1. Drug

    Rupatadine

    go.drugbank.com/drugs/DB11614
    ApprovedInvestigational

    Rupatadine is a dual histamine H1 receptor and platelet activating factor receptor antagonist that is used for symptomatic relief in seasonal and perennial rhinitis as well as chronic spontaneous urticaria

    Categories: Cytochrome P-450 Substrates, Heterocyclic Compounds, 1-RingProducts: RUPAFIN® 10 MG, RUPAFİN 1 MG / ML ORAL ÇÖZELTİ, 120 ML
  2. Drug

    Zorubicin

    go.drugbank.com/drugs/DB11618
    Experimental

    Zorubicin is a drug of the anthracycline class - a class of medications that have historically demonstrated effective chemotherapy for a variety of cancer types.

    Synonyms: Benzoic acid hydrazide, 3-hydrazone with daunorubicin
  3. Drug

    Tasonermin

    go.drugbank.com/drugs/DB11626
    Approved

    Tasonermin is recombinant soluble form tumor necrosis factor α produced via Escherichia coli cell culture. It was approved for use by the European Medicines Agency in April of 1999 for use as an adjunt to surgery for the subsequent remov...

  4. Drug

    Laropiprant

    go.drugbank.com/drugs/DB11629
    ApprovedWithdrawn

    Laropiprant is an ingredient in the EMA-withdrawn product Pelzont.

    Mixtures: CORDAPTIVE®Categories: Heterocyclic Compounds, 2-Ring
  5. Drug

    Recombinant Cholera Toxin B Subunit

    go.drugbank.com/drugs/DB11643
    ApprovedInvestigational

    Recombinant Cholera Toxin B Subunit is an ingredient in the EMA-authorised product Dukoral.

    Synonyms: Cholera enterotoxin B chain, Cholera enterotoxin subunit BCategories: Compounds used in a research, industrial, or household setting
  6. Drug

    PF-4191834

    go.drugbank.com/drugs/DB11645
    Investigational

    PF-4191834 has been investigated for the basic science of Asthma.

    Categories: Heterocyclic Compounds, 1-Ring
  7. Drug

    Tucatinib

    go.drugbank.com/drugs/DB11652
    ApprovedInvestigational

    Tucatinib is a kinase inhibitor drug used with [trastuzumab] and [capecitabine] in the treatment of unresectable or metastatic HER-2 positive breast cancer. … [L12951] Tucatinib is a promising new treatment for patients with metastatic breast cancer who have not responded adequately to other chemotherapy regimens.[L12945]

    Categories: MATE 1 Inhibitors, MATE 2 Inhibitors
  8. Drug

    Evacetrapib

    go.drugbank.com/drugs/DB11655
    Investigational

    Evacetrapib has been used in trials studying the basic science and treatment of Dyslipidemia, Hyperlipidemia, Hypercholesterolemia, Hepatic Insufficiency, and Cardiovascular Disease.

    Categories: Heterocyclic Compounds, 2-Ring
  9. Drug

    Latanoprostene bunod

    go.drugbank.com/drugs/DB11660
    Approved

    In comparison, both latanoprost and latanoprostene bunod contain a latanoprost acid backbone. … As of November 2, 2017 the FDA approved Bausch + Lomb's Vyzulta (latanoprostene bunod opthalmic solution), 0.024% for the indication of reducing intraocular pressure in patients with open-angle glaucoma

  10. Drug

    Eptacog alfa pegol (activated)

    go.drugbank.com/drugs/DB11661
    Investigational

    A With Inhibitors. … Eptacog alfa pegol (activated) has been used in trials studying the prevention and treatment of Haemophilia A, Haemophilia B, Congenital Bleeding Disorder, Haemophilia B With Inhibitors, and Haemophilia